Please login to the form below
cardiovascular diseases
This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.
Ionis reports positive phase 2b results for fesomersen in thrombosis prevention
2b study of fesomersen in patients with ESRD, which we believe supports continued advancement of this potential novel anti-thrombotic therapy for patients with renal and cardiovascular diseases.
Latest news
-
World Heart Day highlights actions to prevent and control cardiovascular disease
The World Heart Federation’s annual World Heart Day takes place today, to highlight the actions that individuals can take to prevent and control cardiovascular disease (CVD). ... If we want to prevent cardiovascular diseases, it is time we take care of
-
Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
In total, IHI will contribute up to 135m to projects funded under IHI call 1, a single-stage call with topics on cancer, neurodegenerative diseases and health data. ... Call 2 includes a total of two topics. The first aims to provide tools for the
-
AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising
He continued: “The results presented today are a result of pushing new boundaries in the treatment of cardiovascular and other ischaemic vascular diseases and address serious unmet needs with the goal ... AstraZeneca and Moderna signed their first
-
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
This acquisition is a testament to Prothena’s pioneering work in ATTR amyloidosis and Novo Nordisk’s dedication to advancing new disease-modifying therapies for the benefit of people with cardiovascular ... diseases that are the world’s leading
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Mavacamten represents Bristol Myers Squibb’s ongoing dedication to improving
More from news
Approximately 5 fully matching, plus 104 partially matching documents found.
Latest Intelligence
-
Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease
Cardiovascular diseases (CVD) are the leading cause of death globally, accounting for 32% of all deaths, according to WHO statistics. ... So-Young Kim is VP Head TA Thrombosis &Vascular Diseases, Clinical Development at Bayer AG.
-
The promise of precision medicine
Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... In Qatar, research into genomics and precision medicine is being used to tackle diseases such as obesity, diabetes and cardiovascular disease.
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
As we continue to follow the science to understand the underlying mechanisms of associated cardiovascular, renal and metabolic diseases, we are working to address shared risk factors and develop solutions designed ... Joris Silon is Senior Vice President,
-
On our best behaviour
The main disease areas of focus have understandably been chronic diseases, including obesity, diabetes, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). ... A shift in behaviour could be very beneficial for pharma. With
-
Can protein degraders unlock ‘undruggable’ drug targets?
Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a ... Big pharma and new start-ups. Arvinas recently attracted a $750m
More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest appointments
-
McCann Health France strengthens team with two new hires
Initially, she worked on the research and development of new drugs in cardiovascular and metabolic diseases before specialising in oncology and onco-haematology.
-
Genmab hires first chief operating officer
Most recently, he led Bristol-Myers Squibb’s US innovative medicines unit, where he managed a team of over 1000 people focused on immunology and cardiovascular diseases.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;
-
MyoKardia appoints COO and medical affairs VP
Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Will the NHS be safe in Liz Truss’s Hands?
Expect a growing debate about the poor health outcomes for patients with major diseases such as cancer, cardiovascular disease and more.
-
Cardiovascular disease: The scale of the challenge
Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. ... This first CVDPREVENT audit is a
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Further to this, the tests used to diagnose cardiac diseases function differently between men and women. ... However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of
-
World Heart Day 2020: It's time to make our clinical trials more inclusive
September 29th is World Heart Day, a day dedicated to raising awareness about cardiovascular diseases and how everyone can take steps to prevent them. ... Cardiovascular diseases affect ethnic minorities more than white people, with South Asians being
-
Hanover Communications
Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. ... COVID-19 has changed the way we must
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- Eli Lilly announces $450m investment in US manufacturing site
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Sandoz’s high concentration Hyrimoz formulation recommended for use in EU
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
